PCA
CYTK icon

Peddock Capital Advisors’s Cytokinetics CYTK Stock Holding History

Peddock Capital Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-261
Closed -$2K – 238
2016
Q3 		$2K Buy
+261
New +$2.73K ﹤0.01% 224

Other funds holding CYTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Peddock Capital Advisors's CYTK Position: Q4 2016 in Review

Peddock Capital Advisors sold out of Cytokinetics (CYTK) in Q4 2016, closing a stake of 261 shares — an estimated $2K sold.

Peddock Capital Advisors first reported a position in CYTK in Q3 2016 and held it in 1 quarter. The position peaked at $2K in Q3 2016. 101 funds tracked by Wall St. Rank hold CYTK as of Q4 2016.

  • Peddock Capital Advisors reported no remaining Cytokinetics position as of Q4 2016 after selling out during the quarter.
  • Peddock Capital Advisors sold 261 Cytokinetics shares in Q4 2016, an estimated $2K.
  • Peddock Capital Advisors first reported a position in Cytokinetics in Q3 2016 and held it in 1 quarter.
  • Peddock Capital Advisors's Cytokinetics position peaked at $2K in Q3 2016.
  • 101 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2016.

Based on Peddock Capital Advisors's 13F filing for Q4 2016, filed 3 Feb 2017.